G1 Therapeutics Executives Sell Shares to Cover Tax Obligations
| Reporter Name | Relationship | Type | Amount | SEC Filing |
|---|---|---|---|---|
| Bailey John E. (Jack) Jr. | President and CEO | Sell | $178,421 | Form 4 |
| Avagliano Mark | Chief Business Officer | Sell | $39,033 | Form 4 |
| Malik Rajesh | Chief Medical Officer | Sell | $39,033 | Form 4 |
| Murdock Terry L | Chief Operating Officer | Sell | $39,033 | Form 4 |
| Umstead John W. V | Chief Financial Officer | Sell | $39,033 | Form 4 |
| Perry Andrew | Chief Commercial Officer | Sell | $39,033 | Form 4 |
Several executives at G1 Therapeutics have sold shares of the company's common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs). The transactions all took place on May 13, 2024, at a weighted average price of $4.7888 per share.
John E. Bailey Jr., President and CEO, sold 37,258 shares for a total of $178,421, leaving him with 452,336 shares. Mark Avagliano, Chief Business Officer, sold 8,151 shares, totaling $39,033, and now directly owns 209,683 shares. Malik Rajesh, Chief Medical Officer, also sold 8,151 shares for $39,033, with his direct ownership at 161,787 shares post-transaction. Terry L Murdock, Chief Operating Officer, sold 8,151 shares for $39,033, reducing his direct ownership to 95,487 shares. John W. V Umstead, Chief Financial Officer, sold 8,151 shares, totaling $39,033, and now owns 153,245 shares. Lastly, Perry Andrew, Chief Commercial Officer, sold 8,151 shares for $39,033, leaving him with 78,951 shares.